press releases 2008  

•  July, 16 - Wacker validates scalability of Anticalin^® production with E.coli secretion technology and will produce Pieris first clinical candidate PRS-050 
  
  
• March, 27 - Pieris raises € 25 M (US$ 38 M) in Series B financing round led by OrbiMed Advisors LLC  
  

 press releases 2007 

• November, 8 - Pieris strengthens its management, as it prepares for the clinical development of PRS-050, an Anticalin^®-based novel cancer therapy   
  
  
• October, 30 - Pieris and Pepscan to identify GPCR-specific Anticalins^® using CLIPS™ protein mimicry technology     
   
• September, 5 - Pieris validates the use of Anticalins^® as ophthalmologic biotherapeutics   
  
  
• July, 10 - Pieris progresses proprietary asthma program: validation of pulmonary delivery of Anticalin^®-based protein product candidate     
  

• June, 21 - Pieris progresses development of its proprietary biotherapeutics platform: successful demonstration of dual targeting with Duocalin^® technology      

• March, 29 - Pieris demonstrates potent anti-tumor activity of a VEGF-specific Anticalin^® in preclinical studies